JP7237590B6 - 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト - Google Patents

肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト Download PDF

Info

Publication number
JP7237590B6
JP7237590B6 JP2018546872A JP2018546872A JP7237590B6 JP 7237590 B6 JP7237590 B6 JP 7237590B6 JP 2018546872 A JP2018546872 A JP 2018546872A JP 2018546872 A JP2018546872 A JP 2018546872A JP 7237590 B6 JP7237590 B6 JP 7237590B6
Authority
JP
Japan
Prior art keywords
peptide
dose
glp
administered
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018546872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510014A5 (https=
JP7237590B2 (ja
JP2019510014A (ja
Inventor
マリア・アレクサンドラ・ベドナレック
ルッツ・ウルリッヒ・イェルムトゥス
フィリップ・アンベリー
マルチェッラ・ペトローネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2019510014A publication Critical patent/JP2019510014A/ja
Priority to JP2022177486A priority Critical patent/JP2023011864A/ja
Publication of JP2019510014A5 publication Critical patent/JP2019510014A5/ja
Application granted granted Critical
Publication of JP7237590B2 publication Critical patent/JP7237590B2/ja
Publication of JP7237590B6 publication Critical patent/JP7237590B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2018546872A 2016-03-10 2017-03-10 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト Active JP7237590B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022177486A JP2023011864A (ja) 2016-03-10 2022-11-04 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306121P 2016-03-10 2016-03-10
US62/306,121 2016-03-10
PCT/EP2017/055679 WO2017153575A1 (en) 2016-03-10 2017-03-10 Glucagon and glp-1 co-agonists for the treatment of obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022177486A Division JP2023011864A (ja) 2016-03-10 2022-11-04 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト

Publications (4)

Publication Number Publication Date
JP2019510014A JP2019510014A (ja) 2019-04-11
JP2019510014A5 JP2019510014A5 (https=) 2022-11-24
JP7237590B2 JP7237590B2 (ja) 2023-03-13
JP7237590B6 true JP7237590B6 (ja) 2023-03-28

Family

ID=58266629

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018546872A Active JP7237590B6 (ja) 2016-03-10 2017-03-10 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト
JP2022177486A Pending JP2023011864A (ja) 2016-03-10 2022-11-04 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022177486A Pending JP2023011864A (ja) 2016-03-10 2022-11-04 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト

Country Status (19)

Country Link
US (3) US10676517B2 (https=)
EP (1) EP3426284B1 (https=)
JP (2) JP7237590B6 (https=)
KR (2) KR20220150416A (https=)
CN (1) CN108697769A (https=)
AR (1) AR107890A1 (https=)
AU (2) AU2017229530B2 (https=)
BR (1) BR112018067731A2 (https=)
CA (1) CA3015922A1 (https=)
EA (1) EA201891946A1 (https=)
ES (1) ES2983409T3 (https=)
IL (1) IL261528B2 (https=)
MX (1) MX2018010640A (https=)
MY (1) MY191321A (https=)
NZ (1) NZ746784A (https=)
SG (2) SG11201806342SA (https=)
TW (1) TWI793069B (https=)
WO (1) WO2017153575A1 (https=)
ZA (1) ZA201806637B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3139613A1 (en) * 2019-05-21 2020-11-26 Medimmune Limited Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
EA202290107A1 (ru) 2019-07-01 2022-03-29 Медиммун Лимитед Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1
KR102812908B1 (ko) 2019-08-19 2025-05-28 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
JP2023505126A (ja) * 2019-12-03 2023-02-08 メディミューン，エルエルシー 肥満症の処置のためのグルカゴン及びｇｌｐ－１のコアゴニストを使用する組合せ治療
AR120714A1 (es) 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
TW202140061A (zh) 2020-01-10 2021-11-01 英商梅迪繆思有限公司 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
CN115397455A (zh) * 2020-01-16 2022-11-25 上海仁会生物制药股份有限公司 Glp-1给药方案
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
KR20230005289A (ko) 2020-04-24 2023-01-09 베링거 인겔하임 인터내셔날 게엠베하 지방 간 질환 및 지방간염의 치료에서 장시간-작용성 glp-1/글루카곤 수용체 작용제로서 글루카곤 유사체
CA3201539A1 (en) * 2020-12-07 2022-06-16 Vyjayanthi Krishnan Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
KR20240043778A (ko) 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
US20230374096A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
CN115975057B (zh) * 2023-03-16 2023-05-16 杭州信海医药科技有限公司 一种可妥度肽的固相合成方法
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
KR20250067206A (ko) 2023-11-07 2025-05-15 주식회사 천농바이오푸드 대사성 질환의 예방, 개선 또는 치료 효과를 갖는 채소 추출복합물 및 이의 용도

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524410A (ja) 2008-06-16 2011-09-01 サノフイ−アベンテイス Ｈｓｐ９０の阻害剤であるピロロインドールの新規誘導体、これらを含有する組成物、およびこれらの使用
JP2011524419A (ja) 2008-06-17 2011-09-01 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション グルカゴン／ｇｌｐ−１受容体コアゴニスト
WO2012138941A1 (en) 2011-04-05 2012-10-11 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
JP2013545724A (ja) 2010-09-28 2013-12-26 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 作用持続時間が増した改変ポリペプチド
JP2015524427A (ja) 2012-07-25 2015-08-24 ハンミ ファーマシューティカル カンパニー リミテッド オキシントモジュリン誘導体を含む高脂血症の治療のための組成物
JP2016501256A (ja) 2012-12-11 2016-01-18 メディミューン リミテッド 肥満を治療するためのグルカゴン／ｇｌｐ−１アゴニスト

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
AU2010272944B2 (en) * 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
WO2012088379A2 (en) * 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
AU2013366692B2 (en) * 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524410A (ja) 2008-06-16 2011-09-01 サノフイ−アベンテイス Ｈｓｐ９０の阻害剤であるピロロインドールの新規誘導体、これらを含有する組成物、およびこれらの使用
JP2011524419A (ja) 2008-06-17 2011-09-01 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション グルカゴン／ｇｌｐ−１受容体コアゴニスト
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
JP2013545724A (ja) 2010-09-28 2013-12-26 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 作用持続時間が増した改変ポリペプチド
WO2012138941A1 (en) 2011-04-05 2012-10-11 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
JP2015524427A (ja) 2012-07-25 2015-08-24 ハンミ ファーマシューティカル カンパニー リミテッド オキシントモジュリン誘導体を含む高脂血症の治療のための組成物
JP2016501256A (ja) 2012-12-11 2016-01-18 メディミューン リミテッド 肥満を治療するためのグルカゴン／ｇｌｐ−１アゴニスト

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
肝臓，Vol.55 Suppl.1，p.A54(PD1-14)

Also Published As

Publication number Publication date
KR20180120739A (ko) 2018-11-06
AU2020202381A1 (en) 2020-04-30
AR107890A1 (es) 2018-06-28
ZA201806637B (en) 2019-07-31
KR102460198B1 (ko) 2022-10-31
IL261528B2 (en) 2023-09-01
US10676517B2 (en) 2020-06-09
KR20220150416A (ko) 2022-11-10
EP3426284B1 (en) 2024-05-08
CA3015922A1 (en) 2017-09-14
SG11201806342SA (en) 2018-08-30
IL261528A (en) 2018-10-31
EP3426284A1 (en) 2019-01-16
WO2017153575A1 (en) 2017-09-14
NZ746784A (en) 2022-11-25
IL261528B1 (en) 2023-05-01
TW201733613A (zh) 2017-10-01
EA201891946A1 (ru) 2019-04-30
TWI793069B (zh) 2023-02-21
SG10202109721PA (en) 2021-10-28
CN108697769A (zh) 2018-10-23
US20220041681A1 (en) 2022-02-10
JP7237590B2 (ja) 2023-03-13
US20190185537A1 (en) 2019-06-20
ES2983409T3 (es) 2024-10-23
JP2019510014A (ja) 2019-04-11
BR112018067731A2 (pt) 2019-01-08
MY191321A (en) 2022-06-15
JP2023011864A (ja) 2023-01-24
AU2017229530B2 (en) 2020-05-07
AU2017229530A1 (en) 2018-10-25
US20200354426A1 (en) 2020-11-12
MX2018010640A (es) 2019-06-13

Similar Documents

Publication Publication Date Title
JP7237590B6 (ja) 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト
US11230584B2 (en) Glucagon/GLP-1 agonists for the treatment of obesity
JP2019510014A5 (https=)
JP2016512213A (ja) 肥満の治療のためのペグ化グルカゴン及びｇｌｐ−１コアゴニスト
NZ785999A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
EA043848B1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
HK40010017A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
HK40010017B (en) Glucagon and glp-1 co-agonists for the treatment of obesity
HK1216179B (en) Glucagon/glp-1 agonists for the treatment of obesity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200305

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220705

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221114

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221122

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221227

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230301

R150 Certificate of patent or registration of utility model

Ref document number: 7237590

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150